Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Inclusion Criteria: * Subjects diagnosed with LCA or RP (with a mutation in either RPE65 or LRAT) * Subjects with LCA must be 5-65 years of age * Subjects with RP must be 18-65 years of age * Subjects who have a "best-corrected" visual acuity of 3 letters or better (20/800 Snellen equivalent) or viable photoreceptors on OCT/FAF. Exclusion Criteria: * Subjects who are actively participating in an experimental therapy study or who have received experimental therapy within 60 days of Day 0. * Subjects with any clinically important abnormal physical finding at Screening. * Subjects who have taken any prescription or investigational oral retinoid medication (e.g., Accutane,® Soriatane®) within 6 months of Day 0 and subjects who did not tolerate their previous oral retinoid medication will be excluded regardless of the time of last exposure. * Subjects with a history of diabetes or chronic hyperlipidemia, hepatitis, pancreatitis, or cirrhosis. * Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days of screening